Phase 3 trials demonstrated ENCELTO significantly slowed macular photoreceptor loss in MacTel patients over 24 months.
Regulators have approved the drug as a treatment for weight loss, Type 2 diabetes and lowering the ... [+] risk of heart attacks and strokes. The FDA said Ozempic can be used to reduce the risk of ...